NOMAD POWER SOLUTIONS, INC.
Close on Oct 19, 2026
- Market cap
- $50.26M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Nomad Power Solutions has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Nomad Power Solutions filed with the SEC
POWER SOLUTIONS LAUNCHES NATIONWIDE MOBILE POWER DEMONSTRATION TOUR
Regulation FD disclosure · EX-99.1 to Form 8-K
Power Solutions Announces Options Trading Begins on Cboe Options Exchange
Regulation FD disclosure · EX-99.1 to Form 8-K
Increases Voyager Fleet Energy Storage by up to 56%, Bringing Eagle and Falcon to 2.025 MWh
Regulation FD disclosure · EX-99.1 to Form 8-K
COMPLETES MERGER WITH NOMAD TRANSPORTABLE POWER SYSTEMS
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Biotechnology Holdings, Inc. Announces Closing of approximately $16.6 Million
Material agreement · Other events · EX-99.1 to Form 8-K
Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
as CEO of its Liora Technologies Europe Ltd. Subsidiary
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
and its Collaborators Expand Clear Cell Ovarian Cancer Trial
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Material agreement · Agreement terminated · Other events · EX-99.1 to Form 8-K
Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
Material agreement · Acquisition or disposition completed · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Biotechnology Holdings Makes $2.6 Million
Regulation FD disclosure · EX-99.1 to Form 8-K
Biotechnology Holdings Appoints Two New Board Members
Executive or director change · Other events · EX-99.1 to Form 8-K
Biotechnology Holdings Provides Corporate Update
Other events · EX-99.1 to Form 8-K
Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency
Other events · EX-99.1 to Form 8-K
Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements
Other events · EX-99.1 to Form 8-K
Clinical Findings Published in Scientific Journal Nature
Other events · EX-99.1 to Form 8-K
Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100
Other events · EX-99.1 to Form 8-K
Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer
Other events · EX-99.1 to Form 8-K
Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
Other events · EX-99.1 to Form 8-K
Adds Northwestern University’s Lurie Cancer Center
Other events · EX-99.1 to Form 8-K
Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Receives U.S. Patent Issue Notification for Immune Oncology
Other events · EX-99.1 to Form 8-K
Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major
Other events · EX-99.1 to Form 8-K
Biotechnology Holdings to Present at Two Investor Conferences
Other events · EX-99.1 to Form 8-K
Biotechnology Provides Update On Recent Activities and Developments
Other events · EX-99.2 to Form 8-K
Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
Other events · EX-99.1 to Form 8-K
Oncologist Jan Schellens as Chief Medical Officer
Material agreement · Executive or director change · Other events · EX-99.1 to Form 8-K
Biotechnology Holdings Provides Update on Recent Activities
Other events · EX-99.1 to Form 8-K
Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
Other events · EX-99.1 to Form 8-K
SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS
Other events · EX-99.1 to Form 8-K
Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
Other events · EX-99.1 to Form 8-K
René Bernards to Present New Pre-Clinical Data
Other events · EX-99.1 to Form 8-K
Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
Material agreement · Other events · EX-99.1 to Form 8-K
Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial
Other events · EX-99.1 to Form 8-K